We are live on ! Find out more
EP

Elkfork Partners Portfolio holdings

AUM $4.11B
1-Year Est. Return 5.26%
This Fund
S&P 500
This Quarter Est. Return
+14.47%
1 Year Est. Return
+5.26%
3 Year Est. Return
+52.4%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.99B
AUM Growth
+$441M
Cap. Flow
-$32.5M
Cap. Flow %
-0.81%
Top 10 Hldgs %
25.17%
Holding
1,061
New
46
Increased
392
Reduced
202
Closed
28

Top Buys

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$15.3M
2
COF icon
Capital One
COF
+$11.2M
3
ETN icon
Eaton
ETN
+$10.3M
4
FTNT icon
Fortinet
FTNT
+$10M
5
BIIB icon
Biogen
BIIB
+$8.07M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$19.7M
2
BA icon
Boeing
BA
+$17.9M
3
HUM icon
Humana
HUM
+$15.2M
4
CI icon
Cigna
CI
+$14.8M
5
ALL icon
Allstate
ALL
+$11.2M

Sector Composition

Rank Sector Weight
1 Technology 20.19%
2 Financials 15.59%
3 Consumer Discretionary 13.07%
4 Healthcare 11.45%
5 Industrials 9.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ICL icon
1026
ICL Group
ICL
$6.53B
$14K ﹤0.01%
2,750
– –
RETA
1027
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$13K ﹤0.01%
154
-44
-22% -$3.65K
TRQ
1028
DELISTED
Turquoise Hill Resources Ltd
TRQ
$13K ﹤0.01%
799
– –
ASMB icon
1029
Assembly Biosciences
ASMB
$498M
$11K ﹤0.01%
48
-46
-49% -$11.6K
TWST icon
1030
Twist Bioscience
TWST
$5.7B
$11K ﹤0.01%
462
-352
-43% -$7.95K
VCIT icon
1031
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
$66.2B
$10K ﹤0.01%
112
– –
CRNX icon
1032
Crinetics Pharmaceuticals
CRNX
$8.84B
$6K ﹤0.01%
+280
New +$6.88K
MDGL icon
1033
Madrigal Pharmaceuticals
MDGL
$10.8B
$5K ﹤0.01%
44
– –
ARVN icon
1034
Arvinas
ARVN
$518M
– –
-170
Closed -$2K
CHRD icon
1035
Chord Energy
CHRD
$7.9B
– –
-55,272
Closed -$306K
CNDT icon
1036
Conduent
CNDT
$244M
– –
-19,206
Closed -$204K
DLB icon
1037
Dolby
DLB
$5.51B
– –
-12,650
Closed -$782K
FTDR icon
1038
Frontdoor
FTDR
$5.1B
– –
-1,452
Closed -$39K
ACH
1039
Accendra Health
ACH
$237M
– –
-16,966
Closed -$107K
OUT icon
1040
Outfront Media
OUT
$5.61B
– –
-75,650
Closed -$1.35M
PCG icon
1041
PG&E
PCG
$38.3B
– –
-57,426
Closed -$1.36M
PR
1042
Permian Resources
PR
$17.8B
– –
-13,860
Closed -$153K
PTGX icon
1043
Protagonist Therapeutics
PTGX
$8.79B
– –
-442
Closed -$3K
SCCO icon
1044
Southern Copper
SCCO
$143B
– –
-10,563
Closed -$301K
SGMO
1045
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-17,710
Closed -$203K
SRRK icon
1046
Scholar Rock
SRRK
$5.67B
– –
-110
Closed -$2K
TARA icon
1047
Protara Therapeutics
TARA
$220M
– –
-72
Closed -$7K
TPST icon
1048
Tempest Therapeutics
TPST
$13.7M
– –
-1
Closed -$2K
VICI icon
1049
VICI Properties
VICI
$29B
– –
-118,636
Closed -$2.23M
EXPR
1050
DELISTED
Express, Inc.
EXPR
– –
-738
Closed -$75K
39 40 41
42
43

Similar funds

GHCM
Glen Harbor Capital Management San Diego, California $4.82B AUM 4.69% 1-Year Est. Return
FCM
Flinton Capital Management Philadelphia, Pennsylvania $3.22B AUM 4.75% 1-Year Est. Return
NA
Neuburgh Advisers Los Angeles, California $3.22B AUM 3.74% 1-Year Est. Return
FIM
Foresters Investment Management New York $5.05B AUM 5.06% 1-Year Est. Return
MCIM
Meadow Creek Investment Management Atlanta, Georgia $5.09B AUM 5.82% 1-Year Est. Return
TAM
Tyers Asset Management Austin, Texas $3.02B AUM 5.29% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
RCM
Riverhead Capital Management Wilmington, Delaware $2.71B AUM 2.34% 1-Year Est. Return

Elkfork Partners's Q1 2019 Portfolio in Review

As of Q1 2019, Elkfork Partners held 1,061 positions worth $3.99B, up 12% from $3.55B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Elkfork Partners's Q1 2019 filing shows 46 new, 392 increased, 202 reduced and 28 closed positions. Its largest new stake was Celanese: 38,742 shares worth $3.82M. The largest sale was Celgene Corp, an estimated $19.7M.

By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 18% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Elkfork Partners's largest Q1 2019 buy was Celanese: 38,742 shares worth $3.82M.
  • Elkfork Partners added most to Microsoft in Q1 2019, an estimated $15.3M increase.
  • Elkfork Partners's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $19.7M.
  • Elkfork Partners fully exited VICI Properties in Q1 2019, selling an estimated $2.23M.
  • Elkfork Partners's ten largest holdings make up 25% of its $3.99B portfolio in Q1 2019.
  • Elkfork Partners opened 46 new positions and closed 28 in Q1 2019.
  • Elkfork Partners's portfolio value rose 12% quarter-over-quarter to $3.99B.

Based on Elkfork Partners's 13F filing for Q1 2019, filed 13 May 2019.